

TABLE 1 --

Adapted from US EPA, Furniture Flame Retardancy Partnership, Environmental Profiles of Chemical Flame-Retardant Alternatives for Low-Density Polyurethane Foam, Table 4-1 (2005)

Chemical	Chemical Abstract Services Registry Number (CAS#)	% in Formulation	Human Health Effects													Ecotox.		Fate		Breakdown Products		
			Priority Effects							Acute Toxicity	Systemic/Organ Effects	Sensitization (skin)	Sensitization (respiratory)	Irritation/Corrosion (skin)	Irritation/Corrosion (eyes)	Immune System Effects	Acute	Chronic	Persistence	Bioaccumulation	Metabolites	Degradation Products
			Carcinogenic	Mutagenic	Reproductive	Developmental	Endocrine Disruption	Neurological														
Antiblaze 180 and 195 (Albemarle)																						
Tris(1,3-dichloro-2-propyl)Phosphate	13674-87-8	95	M	M	M	M		L	M	L						M	M	M	L			
Antiblaze 182 and 205 (Albemarle)																						
Proprietary A - Chloroalkyl Phosphate (1)			M	M	M	M		L	M	L						M	M	M	L			
Proprietary B - Aryl Phosphate			L	L	M	M		M	M	L						H	H	L	M			
Triphenyl Phosphate	115-86-6		L	L	L	L		L	M	L						H	H	L	L			
Antiblaze V500 (Albemarle)																						
Proprietary C - Chloroalkyl Phosphate (2)			M	L	M	M		L	M	M						M	M	M	L			
Proprietary B - Aryl Phosphate			L	L	M	M		M	M	L						H	H	L	M			
Triphenyl Phosphate	115-86-6		L	L	L	L		L	M	L						H	H	L	L			
Saytex RX-8500 (Albemarle)																						
Proprietary D - Reactive brominated flame retardant			L	L	L	L		M	M	M						M	M	L*	L			
Proprietary B - Aryl Phosphate			L	L	M	M		M	M	L						H	H	L	M			
Triphenyl Phosphate	115-86-6		L	L	L	L		L	M	L						H	H	L	L			
<p>Explanations: H=high concern; M=moderate concern; L=low concern. Colored bold text = based on experimental data. <i>Black italic text</i>= based on analog data or expert judgment.</p> <p>US EPA: 1) did not consider Endocrine Disruption as an endpoint; 2) did not consider metabolites and degradation products in its assesemnt, although it noted where persistent degradation products might be expected; and 3) did not include in Table 4-1: Acute Toxicity (for humans), Sensitization - Respiratory, Irritation/Corrosion - Skin and Eyes, nor Immune System Effects -- however, all of these endpoints were addressed in the Appendices of the report.</p> <p>*US EPA noted that persistent degradation products are expected.</p> <p>Note: US EPA values for Persistence and Bioaccumulation are different than Green Screen values.</p>																						

TABLE 2 --

Adapted from US EPA, Furniture Flame Retardancy Partnership, Environmental Profiles of Chemical Flame-Retardant Alternatives for Low-Density Polyurethane Foam, Table 4-1 (2005)

Chemical	Chemical Abstract Services Registry Number (CAS#)	% in Formulation	Human Health Effects											Ecotox.		Fate		Breakdown Products			
			Priority Effects						Acute Toxicity	Systemic/Organ Effects	Sensitization (skin)	Sensitization (respiratory)	Irritation/Corrosion (skin)	Irritation/Corrosion (eyes)	Immune System Effects	Acute	Chronic	Persistence	Bioaccumulation	Metabolites	Degradation Products
			Carcinogenic	Mutagenic	Reproductive	Developmental	Endocrine Disruption	Neurological													
Saytex RZ-243 (Albemarle)																					
Proprietary E - Tetrabromophthalate diol diester			L	L	L	L		L	M	L						L	H	L*	L		
Proprietary B - Aryl Phosphate			L	L	M	M		M	M	L						H	H	L	M		
Triphenyl Phosphate	115-86-6		L	L	L	L		L	M	L						H	H	L	L		
FR 513 (Ameribrom)																					
Tribromoneopentyl Alcohol	36483-57-5		M	M	M	M		M	M	L						M	M	L*	L		
Firemaster 550 / 552 (Great Lakes)																					
Proprietary F - Halogenated aryl ester			L	L	M	M		L	M	L						H	H	L*	L		
Proprietary G - Triaryl Phosphate, isopropylated			L	L	M	M		M	M	L						H	H	L	M		
Triphenyl Phosphate	115-86-6		L	L	L	L		L	M	L						H	H	L	L		
Proprietary H - Halogenated aryl ester			L	L	M	M		L	M	L						H	H	L*	L		
<p>Explanations: H=high concern; M=moderate concern; L=low concern. Bold text = based on experimental data. <i>Black italic text</i> = based on analog data or expert judgment.</p> <p>US EPA: 1) did not consider Endocrine Disruption as an endpoint; 2) did not consider metabolites and degradation products in its assesemnt, although it noted where persistent degradation products might be expected; and 3) did not include in Table 4-1: Acute Toxicity (for humans), Sensitization - Respiratory, Irritation/Corrosion - Skin and Eyes, nor Immune System Effects -- however, all of these endpoints were addressed in the Appendices of the report.</p> <p>*US EPA noted that persistent degradation products are expected.</p> <p>Note: US EPA values for Persistence and Bioaccumulation are different than Green Screen values.</p>																					

TABLE 3 --

Adapted from US EPA, Furniture Flame Retardancy Partnership, Environmental Profiles of Chemical Flame-Retardant Alternatives for Low-Density Polyurethane Foam, Table 4-1 (2005)

Chemical	Chemical Abstract Services Registry Number (CAS#)	% in Formulation	Human Health Effects											Ecotox.		Fate		Breakdown Products			
			Priority Effects						Acute Toxicity	Systemic/Organ Effects	Sensitization (skin)	Sensitization (respiratory)	Irritation/Corrosion (skin)	Irritation/Corrosion (eyes)	Immune System Effects	Acute	Chronic	Persistence	Bioaccumulation	Metabolites	Degradation Products
			Carcinogenic	Mutagenic	Reproductive	Developmental	Endocrine Disruption	Neurological													
AB 053 / Fyrol FR-2 (Supresta)																					
Tris(1,3-dichloro-2-propyl)Phosphate	13674-87-8		M	M	M	M		L	M	L						M	M	M	L		
AC 003 (Supresta)																					
Proprietary I - Organic Phosphate Ester		92-99	L	L	L	L		L	M	L						H	H	H	L		
Triphenyl Phosphate	115-86-6	1-8	L	L	L	L		L	M	L						H	H	L	L		
AC 073 (Supresta)																					
Triphenyl Phosphate	115-86-6	38-48	L	L	L	L		L	M	L						H	H	L	L		
Proprietary J - Aryl Phosphate		40-46	L	M	L	L		L	M	L						L	H	L	L		
Proprietary K - Aryl Phosphate		12-18	L	L	L	L		L	M	L						L	L	L	L		
Proprietary L - Aryl Phosphate		1-3	L	L	L	L		L	M	L						L	L	L	L		
<p>Explanations: H=high concern; M=moderate concern; L=low concern. Bold text = based on experimental data. <i>Black italic text</i>= based on analog data or expert judgment.</p> <p>US EPA: 1) did not consider Endocrine Disruption as an endpoint; 2) did not consider metabolites and degradation products in its assessemnt, although it noted where persistent degradation products might be expected; and 3) did not include in Table 4-1: Acute Toxicity (for humans), Sensitization - Respiratory, Irritation/Corrosion - Skin and Eyes, nor Immune System Effects -- however, all of these endpoints were addressed in the Appendices of the report.</p> <p>*US EPA noted that persistent degradation products are expected.</p> <p>Note: US EPA values for Persistence and Bioaccumulation are different than Green Screen values.</p>																					